Back to Main

Sector Update: Share Higher Pre-Market; GW Pharmaceuticals Rallies 6% on Results from Study on Epilepsy Treatment

By: MT Newswires
Posted: 6/17/2014 8:55:00 AM
Referenced Stocks: GWPH;CBD;GALE;ISIS;BIIB

Top Healthcare stocks:

JNJ: flat

PFE: flat

ABT: +0.08%

MRK: flat

AMGN: flat

Healthcare shares were fairly flat in pre-market trade on Tuesday.

In healthcare stocks news, GW Pharmaceuticals ( GWPH ) shares were up 6% pre-market after the company said preliminary data from a trial into its Epidiolex treatment for drug-resistant epilepsy showed positive results.

The company released physician reports of efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with GW's investigational cannabidiol ( CBD ) product candidate for a period of 12 weeks.

And, Galena Biopharma, Inc. ( GALE ), a biopharmaceutical company developing and commercializing oncology treatments, completed the enrollment in the company's Phase 2a clinical trial for a ovarian and endometrial cancer prevention treatment.

GALE was up about 7% pre-market.

Finally, Isis Pharmaceuticals ( ISIS ) says it has earned a $10 million milestone payment from Biogen Idec ( BIIB ) associated with the validation of an undisclosed target to treat a neurological disorder. This is the first milestone payment under their 2013 strategic collaboration to advance the treatment of neurological disorders.